secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001193125-25-303895
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation; highlights pipeline progress
--------------------------------------------------------------------------------

- Updated presentation covers [212Pb]VMT-α-NET Phase 1/2a for NETs and [212Pb]VMT01 for melanoma.
- Claims compelling anti-tumor activity, durable disease control, and best-in-class safety for NET trial.
- Presentation notes upcoming data milestones but no specific dates or new financial guidance.
- Pipeline includes PSV359 targeting FAP-α; supply chain with on-demand regional sites.
- No material changes to business or financials disclosed in the 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312525303895/0001193125-25-303895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312525303895/catx-20251201.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-303895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer